MeSH term
Frequency | Condition_Probility | Animals | 4 | 0.0 |
Female | 3 | 0.0 |
Humans | 16 | 0.0 |
Lipoproteins, LDL/metabolism | 2 | 0.0 |
Mice | 4 | 0.0 |
Mice, Knockout | 2 | 0.0 |
Mice, Transgenic | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 14 | 0.0 |
Arteriosclerosis/*metabolism | 2 | 3.0 |
Receptors, Immunologic/genetics/*physiology | 2 | 11.0 |
Polymerase Chain Reaction | 4 | 0.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Receptors, Immunologic/*genetics | 8 | 6.0 |
Genetic Predisposition to Disease/*genetics | 4 | 1.0 |
Male | 12 | 0.0 |
*Mutation | 3 | 0.0 |
Aged | 6 | 0.0 |
Case-Control Studies | 3 | 0.0 |
Chromosomes, Human, Pair 8/*genetics | 2 | 1.0 |
DNA Mutational Analysis | 2 | 0.0 |
Middle Aged | 6 | 0.0 |
Pedigree | 2 | 0.0 |
Prostatic Neoplasms/*genetics | 7 | 4.0 |
Risk Factors | 5 | 0.0 |
Sweden | 2 | 0.0 |
Neoplasm Proteins/*genetics | 2 | 0.0 |
Aged, 80 and over | 2 | 0.0 |
Family | 2 | 0.0 |
Age of Onset | 2 | 0.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
*Germ-Line Mutation | 2 | 0.0 |
Prostatic Neoplasms/epidemiology/*genetics | 2 | 15.0 |
Reference Values | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
